Moleculin Biotech, Inc. (MBRX)
- Previous Close
4.5400 - Open
4.5900 - Bid --
- Ask --
- Day's Range
4.4001 - 4.6500 - 52 Week Range
0.3380 - 6.2400 - Volume
10,300 - Avg. Volume
133,152 - Market Cap (intraday)
10.358M - Beta (5Y Monthly) 1.85
- PE Ratio (TTM)
-- - EPS (TTM)
-15.1500 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
35.00
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.
www.moleculin.comRecent News: MBRX
Performance Overview: MBRX
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MBRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MBRX
Valuation Measures
Market Cap
10.11M
Enterprise Value
-12.86M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.39
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.44
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.73%
Return on Equity (ttm)
-76.07%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-29.77M
Diluted EPS (ttm)
-15.1500
Balance Sheet and Cash Flow
Total Cash (mrq)
23.55M
Total Debt/Equity (mrq)
2.20%
Levered Free Cash Flow (ttm)
-14.6M
Research Analysis: MBRX
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell